The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 10, 2026
Filed:
Aug. 18, 2020
Applicant:
The Regents of the University of California, Oakland, CA (US);
Inventors:
Nancy Lane, Hillsborough, CA (US);
Wei Yao, El Dorado Hills, CA (US);
Assignee:
The Regents of the University of California, Oakland, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/663 (2006.01); A61K 9/00 (2006.01); A61K 35/28 (2015.01); A61K 35/64 (2015.01); A61K 47/54 (2017.01); A61K 47/64 (2017.01); A61P 19/08 (2006.01); A61P 19/10 (2006.01); C07K 5/09 (2006.01);
U.S. Cl.
CPC ...
A61K 31/663 (2013.01); A61K 9/0019 (2013.01); A61K 35/28 (2013.01); A61K 35/64 (2013.01); A61K 47/545 (2017.08); A61K 47/548 (2017.08); A61K 47/64 (2017.08); A61P 19/10 (2018.01); C07K 5/0815 (2013.01);
Abstract
Methods of treating osteonecrosis in a subject are provided. In some embodiments, the method comprises administering to a subject having or suspected of having osteonecrosis a pharmaceutical composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug. In some embodiments, the pharmaceutical composition comprises a conjugate of LLP2A and alendronate (LLP2A-Ale). In some embodiments, the method further comprises administering exogenous mesenchymal stem cells.